News - Razadyne ER (Galantamine Hydrobromide), Once-Daily Treatment, Now Available for Patients With Mild to Moderate Alzheimer's DiseaseTITUSVILLE, NJ -- May 23, 2005 -- Razadyne(TM) ER (galantamine hydrobromide), a new once-daily treatment for the symptoms of mild to moderate Alzheimer's disease, is now available by prescription nationwide. The product is marketed by Ortho-McNeil Neurologics, Inc.Approved by the U.S. Food and Drug Administration (FDA) in December 2004, Razadyne ER contains galantamine hydrobromide -- first approved by the FDA in February 2001 as a twice-daily medication, REMINYL(R). In April 2005, the product name was changed to Razadyne. Approximately two million patients have been treated with REMINYL to date. In clinical trials, Razadyne ER provided comparable efficacy, safety, and tolerability to twice-daily galantamine with the convenience of once-daily dosing.Razadyne ER: FDA Approved Extended Treatment for Alzheimer's Dementia - Associated ContentEach day, families across the United States are struck with the diagnosis that a loved one suffers from Alzheimer's dementia. For both men and women who suffer, this progressive disease marks the beginning of a long and complicated battle in the lateIn an effort to remedy the complications associated with Alzheimer's dementia, Ortho-McNeil Neurologics, Inc., has released an extended release FDA approved drug, Razadyne ER, to aide Alzheimer's patients in regaining some control over the irregular pattern of loss of memory and provide, to some extent, a restoration to a somewhat normal, active and healthy life. For patients who suffer from a mild to moderate Alzheimer's dementia, appropriate testing should be completed to confirm the diagnosis and rule out other complicating health factors. When confirmed as mild to moderate, age-related, Alzheimer's dementia, Razadyne ER may provide the relief needed.